Toxicity and acquired tumor resistance through the activation of alternative angiogenic pathways that sustain tumor vascularization and growth are major disadvantages in anti-angiogenesis therapies, particularly in cancers that rely on pathways other than VEGF [51]. The gene discussed is VEGFA; the disease is neoplasm.